Uncategorized

Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival

Published

3 weeks ago

on

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version